Human Adult Melanocytes
Normal primary adult melanocytes are a vital research tool for a variety of applications from malignant melanoma research to pigmentation studies as well as for cosmetics and skin biology programs. ZenBio isolates normal human adult melanocytes and evaluates purity and function using both Mel-5 staining (figure 1) and the conversion of L-dopa -> dopamelanin (figure 2).
These adult melanocyte cultures are available at 95% purity and are recommended with optimized media formulated specifically to support growth and survival in vitro.
Figure 1 - Mel-5 stained adult melanocytes
Figure 2 - L-dopa conversion in adult melanocytes
ZenBio can also provide Contract Services using our human melanocyte cell system. These services include Proliferation, Cytotoxicity, and Gene Expression Profiling. For a detail consultation, please Contact Us.
A comprehensive list of products and prices can be found at Retail Prices (.PDF).
|MEL-F||Human Adult Melanocytes (0.5x106 cells)||Vial||$456.00|
|MEL-F-NEO||NEONATAL Melanocyte (0.5x106 cells)||Vial||$456.00|
|MEL-2||Melanocyte Growth Media||500ml||$126.00|
|MEL-100||Melanocyte Cryopreservation Medium||100ml||$167.00|
|Recent Publications:||View |
Oncogenic PKC-ι activates Vimentin during epithelial-mesenchymal transition in melanoma; a study based on PKC-ι and PKC-ζ specific inhibitors
Wishrawana S. Ratnayake, Christopher A. Apostolatos, André H. Apostolatos, Ryan J. Schutte, Monica A. Huynh, David A. Ostrov & Mildred Acevedo-Duncan
Two novel atypical PKC inhibitors; ACPD and DNDA effectively mitigate cell proliferation and epithelial to mesenchymal transition of metastatic melanoma while ...
Wishrawana S. Ratnayake André H. Apostolatos David A. Ostrov Mildred Acevedo-Duncan
| Melanoma patient derived xenografts acquire distinct Vemurafenib resistance mechanisms David J Monsma , David M Cherba , Emily E Eugster , Dawna L Dylewski , Paula T Davidson , Chelsea A Peterson , Andrew S Borgman , Mary E Winn , Karl J Dykema , Craig P Webb , Jeffrey P MacKeigan , Nicholas S Duesbery , Brian J Nickoloff, Noel R Monks |
Am J Cancer Res 2015;5(4):1507-1518 www.ajcr.us /ISSN:2156-6976/ajcr0006747